

Requested by Representative MALSTROM

**PROPOSED AMENDMENTS TO  
HOUSE BILL 2645**

1 On page 1 of the printed bill, delete lines 4 through 28 and delete pages  
2 2 through 10 and insert:

3 **“SECTION 1. Definitions. As used in sections 1 to 20 of this 2017  
4 Act:**

5 **“(1) ‘Authorized collector’ means a person that enters into an  
6 agreement with a program operator for the purpose of collecting cov-  
7 ered drugs under a drug take-back program.**

8 **“(2)(a) ‘Covered drug’ means a drug that a covered entity has dis-  
9 carded or abandoned or that a covered entity intends to discard or  
10 abandon.**

11 **“(b) ‘Covered drug’ includes:**

12 **“(A) Prescription drugs, as defined in ORS 689.005;**

13 **“(B) Nonprescription drugs, as defined in ORS 689.005;**

14 **“(C) Drugs marketed under a brand name, as defined in ORS  
15 689.515;**

16 **“(D) Drugs marketed under a generic name, as defined in ORS  
17 689.515;**

18 **“(E) Biological products, as described in ORS 689.522;**

19 **“(F) Drugs intended to be used by a licensed veterinarian; and**

20 **“(G) Combination products.**

21 **“(c) ‘Covered drug’ does not include:**

1       “(A) Vitamins or supplements;

2       “(B) Herbal-based remedies or homeopathic drugs, products or  
3 remedies;

4       “(C) Products that are regulated as both cosmetics and  
5 nonprescription drugs by the federal Food and Drug Administration;

6       “(D) Drugs and biological products for which a covered manufac-  
7 turer administers a drug take-back program as part of a risk evalu-  
8 ation and mitigation strategy under the oversight of the federal Food  
9 and Drug Administration; or

10       “(E) Pet pesticide products.

11       “(3)(a) ‘Covered entity’ means a resident of this state or a non-  
12 business entity located in this state.

13       “(b) ‘Covered entity’ does not include a law enforcement agency or  
14 an entity that generates pharmaceutical waste, such as a hospital,  
15 health care clinic, office of a health care provider, veterinary clinic  
16 or pharmacy.

17       “(4)(a) ‘Covered manufacturer’ means a person that manufactures  
18 prescription drugs, as defined in ORS 689.005, that are sold within this  
19 state.

20       “(b) ‘Covered manufacturer’ does not include:

21       “(A) A person that:

22       “(i) Packages or repackages prescription drugs that are sold within  
23 this state or who labels or relabels the containers of prescription drugs  
24 that are sold within this state; and

25       “(ii) Does not produce, prepare, propagate, compound, convert or  
26 process prescription drugs that are sold within this state; or

27       “(B) A prepaid group practice described in ORS 441.229.

28       “(5) ‘Drop-off site’ means the location where an authorized collector  
29 operates a secure repository for collecting covered drugs.

30       “(6) ‘Drug’ has the meaning given that term in ORS 689.005.

1       **“(7) ‘Drug take-back organization’ means an organization desig-**  
2 **nated by a covered manufacturer or a group of covered manufacturers**  
3 **to act as an agent of the covered manufacturer or group of covered**  
4 **manufacturers for the purpose of participating in a drug take-back**  
5 **program.**

6       **“(8) ‘Drug take-back program’ means a program developed and im-**  
7 **plemented by a program operator for the collection, transportation**  
8 **and disposal of covered drugs for which a plan has been approved un-**  
9 **der section 4 of this 2017 Act.**

10       **“(9) ‘Mail back service’ means a method of collecting covered drugs**  
11 **from a covered entity by using prepaid, preaddressed mailing envel-**  
12 **opes.**

13       **“(10) ‘Manufacture’ has the meaning given that term in ORS**  
14 **689.005.**

15       **“(11) ‘Pharmacy’ has the meaning given that term in ORS 689.005.**

16       **“(12) ‘Potential authorized collector’ means:**

17       **“(a) A person that:**

18       **“(A) Is registered with the Drug Enforcement Administration of the**  
19 **United States Department of Justice; and**

20       **“(B) Qualifies under federal law to collect and dispose of controlled**  
21 **substances, or qualifies under federal law to have the person’s regis-**  
22 **tration modified in such a way that authorizes the person to collect**  
23 **and dispose of controlled substances.**

24       **“(b) A law enforcement agency or other entity not described in**  
25 **paragraph (a) of this subsection, as approved by the Department of**  
26 **Environmental Quality by rule.**

27       **“(13) ‘Program operator’ means a covered manufacturer, group of**  
28 **covered manufacturers or drug take-back organization that develops**  
29 **and implements, or plans to develop and implement, a drug take-back**  
30 **program approved by the department.**

1       “(14) ‘Retail drug outlet’ means a retail drug outlet, as defined in  
2       ORS 689.005, that is open to and accessible by the public.

3       “(15) ‘Wholesale drug outlet’ has the meaning given that term in  
4       ORS 689.005.

5       “SECTION 2. Requirement to Participate in Drug Take-Back Pro-  
6       gram. (1) Except as provided in subsection (2) of this section, each  
7       covered manufacturer shall participate in a drug take-back program  
8       that complies with the requirements of sections 1 to 20 of this 2017 Act.  
9       A covered manufacturer may participate in a drug take-back program  
10      independently, as part of a group of covered manufacturers or by de-  
11      legating the covered manufacturer’s duties under sections 1 to 20 of  
12      this 2017 Act to a drug take-back organization.

13      “(2) A covered manufacturer is not required to participate in a drug  
14      take-back program as described in subsection (1) of this section if the  
15      covered manufacturer manufactures prescription drugs for fewer than  
16      50 patients in this state. A covered manufacturer that manufactures  
17      prescription drugs for fewer than 50 patients in this state must provide  
18      mail back services to those patients instead.

19      “(3) If a covered manufacturer does not participate in a drug take-  
20      back program as described in subsection (1) of this section, and does  
21      not qualify for exemption under subsection (2) of this section, the  
22      State Board of Pharmacy may assess a fine against the covered man-  
23      ufacturer in an amount not to exceed \$1,000 for each day that pre-  
24      scription drugs manufactured by the covered manufacturer are sold in  
25      this state.

26      “SECTION 3. Organization of Program Operator. The program op-  
27      erator of a drug take-back program must be organized as an entity  
28      that is exempt from income taxes under section 501(c)(3) of the Inter-  
29      nal Revenue Code, as amended and in effect on the effective date of  
30      this 2017 Act.

1       **“SECTION 4. Plans and Updated Plans for Drug Take-Back Pro-**  
2 **grams.** (1) In a form and manner prescribed by the Department of  
3 Environmental Quality, a program operator must submit to the de-  
4 partment a plan for participating in a drug take-back program. The  
5 department shall approve a proposed drug take-back program plan if  
6 the program operator submits a completed application, the proposed  
7 drug take-back program meets the requirements of subsection (2) of  
8 this section and the program operator pays the fee established by the  
9 department under section 15 of this 2017 Act.

10       **“(2) To be approved by the department, a proposed drug take-back**  
11 **program plan must:**

12       **“(a) Identify and provide contact information for the program op-**  
13 **erator and each covered manufacturer participating in the proposed**  
14 **drug take-back program;**

15       **“(b) Provide for a collection system that complies with sections 6,**  
16 **7 and 8 of this 2017 Act;**

17       **“(c) Provide for a disposal system that complies with section 9 of**  
18 **this 2017 Act;**

19       **“(d) Include policies and procedures to ensure the safe and secure**  
20 **handling and disposal of covered drugs;**

21       **“(e) Include policies and procedures to ensure the security of pa-**  
22 **tient information that may be printed on the packaging of a covered**  
23 **drug;**

24       **“(f) Set forth a plan to cover all costs associated with the proposed**  
25 **drug take-back program, with the costs of the proposed drug take-back**  
26 **program apportioned among each covered manufacturer participating**  
27 **in the proposed drug take-back program according to the share of**  
28 **revenue that each covered manufacturer participating in the proposed**  
29 **drug take-back program earns from making sales of prescription drugs**  
30 **within this state;**

1       “(g) Set forth short-term and long-term goals with respect to the  
2 amount of covered drugs collected under the proposed drug take-back  
3 program and with respect to fostering public awareness of the pro-  
4 posed drug take-back program; and

5       “(h) Describe how the drug take-back program will provide con-  
6 venient service in every county in this state, including how under the  
7 drug take-back program the program operator will:

8       “(A) Establish at least one drop-off site in each county in this state;

9       “(B) Establish at least one drop-off site in each city in this state  
10 that has 20,000 or more residents; and

11       “(C) Establish additional drop-off sites in each city in this state at  
12 a rate of one drop-off site per 20,000 residents.

13       “(3)(a) The drop-off site required under subsection (2)(h)(A) of this  
14 section may be the same drop-off site as the drop-off site required  
15 under subsection (2)(h)(B) of this section.

16       “(b) The department may waive the requirement of subsection  
17 (2)(h)(A) of this section with respect to an individual county if the  
18 drug take-back program plan describes how the drug take-back pro-  
19 gram will provide mail back service in the county.

20       “(4)(a) Not later than 90 days after receiving a plan under sub-  
21 section (1) of this section, the department shall issue an order either  
22 approving or rejecting the plan. If the department rejects the plan, the  
23 department shall include in the order the reason or reasons for the  
24 rejection.

25       “(b) Not later than 60 days after issuing an order rejecting a plan  
26 under paragraph (a) of this subsection, a program operator must sub-  
27 mit to the department a revised plan for participating in a drug take-  
28 back program. Not later than 90 days after receiving a revised plan  
29 under this paragraph, the department shall issue an order either ap-  
30 proving or rejecting the revised plan. If the department rejects the

1 revised plan, the department shall include in the order the reason or  
2 reasons for the rejection.

3 “(c) If the department issues an order rejecting a revised plan under  
4 paragraph (b) of this subsection, the department may:

5 “(A) Require the program operator to further revise the plan in  
6 accordance with the processes set forth in paragraph (b) of this sub-  
7 section; or

8 “(B) Impose a penalty on each covered manufacturer participating  
9 in the proposed drug take-back program as described in section 14 of  
10 this 2017 Act.

11 “(d) Not later than four years after issuing an order approving a  
12 plan under paragraph (a) of this subsection, a program operator must  
13 submit to the department an updated plan for the continued operation  
14 of a drug take-back program, in which the program operator describes  
15 any substantive changes to the drug take-back program that involve  
16 an element required under subsection (2) of this section. An updated  
17 plan is subject to the approval processes set forth in this subsection.

18 “(5) The department shall make each plan submitted under sub-  
19 section (1) of this section and each revised or updated plan submitted  
20 under subsection (4) of this section available to the public.

21 **“SECTION 5. Changes to Drug Take-Back Programs. (1) In a form**  
22 **and manner prescribed by the Department of Environmental Quality,**  
23 **a program operator must request preapproval from the department for**  
24 **any change to a drug take-back program that substantively alters the**  
25 **drug take-back program. A program operator must make a request**  
26 **under this subsection not later than 60 days before the change is to**  
27 **occur. For purposes of this subsection, the following types of changes**  
28 **substantively alter a drug take-back program:**

29 “(a) Changes to which covered manufacturers are participating in  
30 the drug take-back program;

1       **“(b) Changes involving methods used to collect covered drugs;**  
2       **“(c) Changes involving methods used to dispose of covered drugs;**  
3       **“(d) Changes to the policies and procedures for handling and dis-**  
4 **posing of covered drugs;**

5       **“(e) Changes to the policies and procedures for securing patient**  
6 **information that may be printed on the packaging of a covered drug;**  
7 **and**

8       **“(f) Changes involving methods used to foster public awareness of**  
9 **the proposed drug take-back program.**

10       **“(2) In a form and manner prescribed by the department, a program**  
11 **operator must notify the department of any change to a drug take-**  
12 **back program that does not substantively alter the drug take-back**  
13 **program. A program operator must provide notice under this sub-**  
14 **section not later than 30 days before the change is to occur. For pur-**  
15 **poses of this subsection, the following types of changes do not**  
16 **substantively alter a drug take-back program:**

17       **“(a) Changes to the location of a drop-off site; and**

18       **“(b) Changes to the schedule or location of collection events held**  
19 **pursuant to section 8 of this 2017 Act.**

20       **“(3) In a form and manner prescribed by the department, a program**  
21 **operator must notify the department, not later than 30 days after the**  
22 **change occurs, of any change involving:**

23       **“(a) The contact information for the program operator;**

24       **“(b) The contact information for a covered manufacturer partic-**  
25 **ipating in the drug take-back program; or**

26       **“(c) The ownership of a covered manufacturer participating in the**  
27 **drug take-back program.**

28       **“SECTION 6. Authorized Collectors. (1) Before submitting to the**  
29 **Department of Environmental Quality a plan under section 4 (1) of this**  
30 **2017 Act, a program operator must:**



1       “(a) Solicit potential authorized collectors for the purpose of col-  
2 lecting covered drugs under the drug take-back program; and

3       “(b) Enter into agreements with all willing authorized collectors for  
4 the purpose of collecting covered drugs under the drug take-back  
5 program.

6       “(2) In entering into agreements under this section, a program op-  
7 erator must enter into an agreement, insofar as the agreement is  
8 practicable and cost-effective, with each retail drug outlet, hospital  
9 with an on-site pharmacy, health care clinic with an on-site pharmacy  
10 and law enforcement agency that demonstrates to the program oper-  
11 ator the capability of being an authorized collector.

12       “(3) An agreement entered into under this section must require an  
13 authorized collector to comply with all state laws and rules and federal  
14 laws and regulations governing the keeping of covered drugs, as iden-  
15 tified by the State Board of Pharmacy by rule.

16       “(4) In approving plans and updated plans under section 4 of this  
17 2017 Act, and in preapproving changes under section 5 of this 2017 Act,  
18 the department shall, insofar as is practicable, ensure that each resi-  
19 dent of this state has adequate access to a drop-off site.

20       “SECTION 7. Drop-off Sites. (1) The system by which a program  
21 operator collects covered drugs under a drug take-back program must  
22 be safe and secure to use on an ongoing basis.

23       “(2) For purposes of a drug take-back program:

24       “(a) A drop-off site must be available for use during the normal  
25 business hours of the authorized collector;

26       “(b) A drop-off site must use a secure repository in compliance with  
27 all state laws and rules and federal laws and regulations governing the  
28 keeping of covered drugs in repositories, as identified by the State  
29 Board of Pharmacy by rule;

30       “(c) The secure repository used at a drop-off site must be serviced

1 and emptied as often as necessary to avoid reaching capacity;

2 “(d) A sign must be affixed to the secure repository used at a  
3 drop-off site that prominently displays a toll-free telephone number  
4 and a website address that a covered entity may use to provide feed-  
5 back to the program operator about the drug take-back program; and

6 “(e) If a drop-off site is located at a long-term care facility, as de-  
7 fined in ORS 442.015, only individuals who reside at the long-term care  
8 facility may use the drop-off site.

9 **“SECTION 8. Covered Drug Collection Events.** If a drug take-back  
10 program provides for the periodic collection of covered drugs through  
11 collection events, the collection events must be conducted:

12 “(1) In accordance with the applicable regulations and protocols of  
13 the Drug Enforcement Administration of the United States Depart-  
14 ment of Justice; and

15 “(2) In coordination with the local solid waste management officials  
16 who have jurisdiction over the impacted area.

17 **“SECTION 9. Disposal of Covered Drugs.** Covered drugs collected  
18 at a drop-off site must be disposed of:

19 “(1) At a hazardous waste disposal facility that meets the require-  
20 ments of 40 C.F.R. parts 264 and 265, as in effect on the effective date  
21 of this 2017 Act; or

22 “(2) At a municipal solid waste incinerator that is permitted to ac-  
23 cept pharmaceutical waste.

24 **“SECTION 10. Public Awareness.** (1) A program operator must pro-  
25 mote, and provide public outreach and education about, the safe and  
26 secure collection of covered drugs under the drug take-back program  
27 through the use of a website and written materials provided at the  
28 time a covered drug is delivered to a covered entity, and through the  
29 use of any signage, advertising or other means that the program op-  
30 erator determines is an effective means of fostering public awareness.

1 **At a minimum, a program operator must:**

2 **“(a) Promote the safe and secure storage of covered drugs by cov-**  
3 **ered entities;**

4 **“(b) Disseminate information on the inherent risks of improperly**  
5 **storing or disposing of opioids or opiates;**

6 **“(c) Discourage the disposal of covered drugs in the garbage or**  
7 **sewer system;**

8 **“(d) Promote the disposal of covered drugs through the use of the**  
9 **drug take-back program;**

10 **“(e) Establish a toll-free telephone number and a website address**  
11 **that a covered entity may use to contact the program operator about**  
12 **the drug take-back program;**

13 **“(f) Publicize information on the location of drop-off sites and col-**  
14 **lection processes;**

15 **“(g) Work with authorized collectors to develop a readily recogni-**  
16 **zable and consistent design for repositories to be used at drop-off sites**  
17 **and to develop clear, standardized instructions to covered entities on**  
18 **how to use those repositories; and**

19 **“(h) Conduct a survey once every two years of covered entities and**  
20 **pharmacists, health care providers and veterinarians who interact**  
21 **with covered entities.**

22 **“(2) For purposes of conducting a survey under subsection (1)(h) of**  
23 **this section:**

24 **“(a) In a form and manner prescribed by the Department of Envi-**  
25 **ronmental Quality, a program operator must submit proposed survey**  
26 **questions to the department for preapproval.**

27 **“(b) Surveys must:**

28 **“(A) Measure public awareness of the drug take-back program;**

29 **“(B) Assess the extent to which drop-off sites, collection events and**  
30 **mail back services are convenient and easy to use; and**

1       “(C) Assess knowledge of and attitudes toward the risks posed by  
2 improperly storing covered drugs and improperly discarding or aban-  
3 doning covered drugs.

4       “(3) A program operator shall coordinate with other program oper-  
5 ators under this section to ensure that covered entities can easily  
6 identify, understand and access the services provided by all drug  
7 take-back programs that are operational in this state. At a minimum,  
8 all of the drug take-back programs that are operational in this state  
9 must provide a single toll-free telephone number and a single website  
10 address that a covered entity may use to contact program operators  
11 about the drug take-back programs and to acquire information about  
12 the location of the drop-off sites and the collection processes of the  
13 drug take-back programs.

14       “(4) Upon request, a retail drug outlet, hospital with an on-site  
15 pharmacy or health care clinic with an on-site pharmacy must provide  
16 a covered entity with written materials provided by a program opera-  
17 tor for the purpose of promoting the safe and secure collection of  
18 covered drugs at the time that a covered drug is delivered to a covered  
19 entity.

20       “SECTION 11. Annual Report to the Department of Environmental  
21 Quality. (1) In a form and manner prescribed by the Department of  
22 Environmental Quality, a program operator must submit to the de-  
23 partment an annual report on the development, implementation and  
24 operation of the drug take-back program that includes:

25       “(a) A list of covered manufacturers participating in the drug  
26 take-back program;

27       “(b) The total amount, by weight, of covered drugs collected under  
28 the drug take-back program;

29       “(c) The amount, by weight, of covered drugs collected under each  
30 method of collecting drugs under the drug take-back program;

1       “(d) The address of each drop-off site used under the drug take-back  
2 program;

3       “(e) The date and location of collection events held pursuant to  
4 section 8 of this 2017 Act;

5       “(f) The method or methods used to transport covered drugs col-  
6 lected under the drug take-back program;

7       “(g) The disposal technologies or processes used pursuant to section  
8 9 of this 2017 Act;

9       “(h) Whether any safety or security problems occurred during the  
10 collection, transportation or disposal of covered drugs and, if a prob-  
11 lem occurred, a summary of possible resolutions;

12       “(i) A summary of the drug take-back program’s compliance with  
13 section 10 of this 2017 Act; and

14       “(j) A summary of the annual expenditures of the drug take-back  
15 program.

16       “(2) The department shall review reports submitted under this sec-  
17 tion and approve those that comport with the requirements of this  
18 section. If the department does not approve a report under this sub-  
19 section, the department shall provide the program operator with  
20 written notice of revisions necessary for approval.

21       “(3) The department shall publish approved reports submitted under  
22 this section on a website of the department.

23       “SECTION 12. Funding Drug Take-Back Programs. Each covered  
24 manufacturer or group of covered manufacturers must pay all costs  
25 associated with participating in a drug take-back program. A program  
26 operator or authorized collector may not impose a charge, including  
27 any charge imposed at the time that a covered drug is sold to or col-  
28 lected from a covered entity, against covered entities for the purpose  
29 of recouping the costs of a drug take-back program.

30       “SECTION 13. Inspection and Audit. The Department of Environ-

1 **mental Quality shall ensure compliance with sections 1 to 20 of this**  
2 **2017 Act by:**

3 **“(1) Entering into an agreement with the State Board of Pharmacy**  
4 **whereby the board, during routine inspections of retail drug outlets:**

5 **“(a) Inspects drop-off sites located at retail drug outlets; and**

6 **“(b) Informs the department of drop-off sites that are not in com-**  
7 **pliance with sections 1 to 20 of this 2017 Act;**

8 **“(2) Inspecting drop-off sites not located retail drug outlets; and**

9 **“(3) Auditing the records of program operators.**

10 **“SECTION 14. Enforcement and Discipline. (1)(a) The Department**  
11 **of Environmental Quality shall send notice to a covered manufacturer**  
12 **if the covered manufacturer fails to participate in a drug take-back**  
13 **program as required by sections 1 to 20 of this 2017 Act. Notice sent**  
14 **under this subsection must explain the possible penalties that may be**  
15 **incurred by the covered manufacturer for committing the violation.**

16 **“(b) If, 120 days after the date on which the department sent notice**  
17 **under paragraph (a) of this subsection, the covered manufacturer**  
18 **continues to sell drugs within this state without participating in a**  
19 **drug take-back program, the department may impose a civil penalty**  
20 **against the covered manufacturer for an amount that does not exceed**  
21 **\$10,000 for each day, beginning on the 121st day, that the covered**  
22 **manufacturer commits the violation.**

23 **“(2)(a) The department shall send notice to a program operator if**  
24 **the department determines that the program operator’s drug take-**  
25 **back program is not in compliance with sections 1 to 20 of this 2017**  
26 **Act. Notice sent under this subsection must explain the possible pen-**  
27 **alties that may be incurred by the program operator for committing**  
28 **the violation.**

29 **“(b) If a drug take-back program continues not to be in compliance**  
30 **with sections 1 to 20 of this 2017 Act 30 days after the date on which**

1 the department sent notice under paragraph (a) of this subsection, the  
2 department may:

3 “(A) Impose a civil penalty against the program operator for an  
4 amount that does not exceed \$10,000 for each day, beginning on the  
5 31st day, that the program operator commits the violation; and

6 “(B) If the department determines that the violation presents a risk  
7 to public health and safety, suspend, in whole or in part, operation of  
8 the drug take-back program.

9 “(3) The department shall deposit moneys collected through the  
10 imposition of civil penalties under this section into the Secure Drug  
11 Take-Back Account established under section 16 of this 2017 Act.

12 **“SECTION 15. Fees.** (1) The Department of Environmental Quality  
13 shall establish the following fees for the purpose of paying the costs  
14 of administering sections 1 to 20 of this 2017 Act.

15 “(a) A one-time fee for reviewing a drug take-back program plan  
16 submitted under section 4 of this 2017 Act.

17 “(b) An annual fee for expenses associated with the ongoing costs  
18 of administering sections 1 to 20 of this 2017 Act.

19 “(c) An hourly fee for any other work that the department must  
20 do on behalf of a drug take-back program.

21 “(2) Fees established under subsection (1) of this section must be  
22 reasonably calculated to pay the expenses associated with the purpose  
23 for which the fee is collected.

24 “(3) The department shall deposit fee moneys collected pursuant to  
25 this section into the Secure Drug Take-Back Account established un-  
26 der section 16 of this 2017 Act.

27 **“SECTION 16. Secure Drug Take-Back Account.** (1) There is estab-  
28 lished in the State Treasury, separate and distinct from the General  
29 Fund, the Secure Drug Take-Back Account. Interest earned by the  
30 account shall be credited to the account. All moneys in the account

1 are continuously appropriated to the Department of Environmental  
2 Quality purposes of administering sections 1 to 20 of this 2017 Act.

3 “(2) The Secure Drug Take-Back Account shall consist of all mon-  
4 eys deposited into or credited to the account, including:

5 “(a) Moneys collected under and deposited into the account pursu-  
6 ant to sections 14 and 15 of this 2017 Act; and

7 “(b) Moneys appropriated or transferred to the account by the  
8 Legislative Assembly.

9 “SECTION 16a. Liability. An authorized collector, covered man-  
10 ufacturer, drug take-back organization, drug take-back program, po-  
11 tential authorized collector and program operator may not be held  
12 criminally or civilly liable for any function, duty or power performed  
13 for the purpose of complying with sections 1 to 20 of this 2017 Act,  
14 unless the function, duty or power was performed with gross  
15 negligence or willful and wanton misconduct.

16 “SECTION 17. Antitrust Immunity. The Legislative Assembly de-  
17 clares that program operators providing covered entities with drug  
18 take-back program services, including the safe and secure collection,  
19 transportation and disposal of covered drugs, is in the best interests  
20 of the public. Therefore, the Legislative Assembly declares its intent  
21 that participating in drug take-back programs as required by sections  
22 1 to 20 of this 2017 Act shall be exempt from state antitrust laws. The  
23 Legislative Assembly further declares its intent to provide immunity  
24 for participating in drug take-back programs as required by sections  
25 1 to 20 of this 2017 Act from federal antitrust laws. This section does  
26 not authorize any person to engage in activities or to conspire to en-  
27 gage in activities that constitute per se violations of state or federal  
28 antitrust laws that are not authorized under sections 1 to 20 of this  
29 2017 Act.

30 “SECTION 18. Confidentiality. Any proprietary information or any



1 financial, manufacturing or sales information or data that the De-  
2 partment of Environmental Quality receives from a covered manufac-  
3 turer or drug take-back organization under sections 1 to 20 of this 2017  
4 Act is confidential and not subject to public disclosure under ORS  
5 192.410 to 192.505, except that the department may disclose summarized  
6 information or aggregated data if the information or data does not  
7 directly or indirectly identify the proprietary information or the fi-  
8 nancial, manufacturing or sales information or data of a specific cov-  
9 ered manufacturer or drug take-back organization.

10 “SECTION 19. Nonapplicability of the Uniform Controlled Sub-  
11 stances Act. The provisions of ORS chapter 475 do not apply to a pro-  
12 gram operator, insofar as the program operator is collecting,  
13 transporting and disposing of covered drugs pursuant to sections 1 to  
14 20 of this 2017 Act.

15 “SECTION 19a. Moratorium. Except as expressly authorized by  
16 state law, the governing body of a city or a county may not enact an  
17 ordinance requiring, or otherwise establishing a program for, the col-  
18 lection of covered drugs by nongovernmental entities through the use  
19 of drop-off sites or mail back services.

20 “SECTION 20. Rulemaking. The Department of Environmental  
21 Quality shall adopt any rules necessary for the effective adminis-  
22 tration of sections 1 to 20 of this 2017 Act. Upon request, the State  
23 Board of Pharmacy shall assist the department in adopting rules under  
24 this section.

25 “SECTION 21. Report to the Legislative Assembly. Not later than  
26 September 15, 2019, the Department of Environmental Quality shall  
27 submit a report to the Legislative Assembly, in the manner provided  
28 by ORS 192.245, describing the department’s administration of sections  
29 1 to 20 of this 2017 Act. The report must include:

30 “(1) An evaluation of whether the collection of covered drugs by

1 **drug take-back programs that are operational in this state is safe and**  
2 **secure;**

3 **“(2) A summary of available data on whether the drug take-back**  
4 **programs are effective at reducing the risks posed by improperly**  
5 **stored covered drugs and improperly discarded or abandoned covered**  
6 **drugs; and**

7 **“(3) A comprehensive review of the strategies employed by drug**  
8 **take-back programs to achieve the requirements of sections 1 to 20 of**  
9 **this 2017 Act.**

10 **“SECTION 21a. Repeals. (1) Sections 1 to 20 of this 2017 Act are re-**  
11 **pealed on September 15, 2029.**

12 **“(2) Section 21 of this 2017 Act is repealed on December 31, 2019.**

13 **“SECTION 22. Required Date for Initial Participation. (1) Each**  
14 **program operator, as defined in section 1 of this 2017 Act, shall submit**  
15 **to the Department of Environmental Quality a plan for participating**  
16 **in a drug take-back program as required by section 4 (1) of this 2017**  
17 **Act on or before July 1, 2018.**

18 **“(2) Each drug take-back program must be operational by February**  
19 **1, 2019.**

20 **“SECTION 23. Operative Date. (1) Sections 1 to 20 of this 2017 Act**  
21 **become operative on January 1, 2018.**

22 **“(2) The Department of Environmental Quality and the State Board**  
23 **of Pharmacy may take any action before the operative date specified**  
24 **in subsection (1) of this section that is necessary to enable the de-**  
25 **partment or board to exercise, on and after the operative date specified**  
26 **in subsection (1) of this section, all the duties, powers and functions**  
27 **conferred on the department or board by sections 1 to 20 of this 2017**  
28 **Act.**

29 **“SECTION 24. Captions. The section captions used in this 2017 Act**  
30 **are provided only for the convenience of the reader and do not become**

1 part of the statutory law of this state or express any legislative intent  
2 in the enactment of this 2017 Act.

3 **“SECTION 25. Effective Date. This 2017 Act takes effect on the 91st**  
4 **day after the date on which the 2017 regular session of the Seventy-**  
5 **ninth Legislative Assembly adjourns sine die.”.**

6

---